RACHEL WHITMAN: Open Payments
NPI 1356741151 · PORTSMOUTH, NH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$575 in 19 payments from 10 companies in 2025. Trend: 2023 $896 · 2024 $748 · 2025 $575
Food & beverage: $575
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 5 | $125 |
| GENZYME CORPORATION | 3 | $105 |
| Phathom Pharmaceuticals, Inc. | 1 | $104 |
| Gilead Sciences, Inc. | 2 | $50 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $47 |
| PFIZER INC. | 2 | $39 |
| QOL Medical, LLC | 1 | $38 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $24 |
| Novo Nordisk Inc | 1 | $22 |
| Organon LLC | 1 | $21 |
Products named: DUPIXENT, VOQUEZNA, ENTYVIO, CREON, XELJANZ, Sucraid, RINVOQ, LINZESS.
Industry payments across NH — which companies pay providers there.
